RV and BTZ combination therapy CI values
| Cell line . | Dose 1: ED50/8 . | Dose 2: ED50/4 . | Dose 3: ED50/2 . | Dose 4: ED50 . | Dose 5: 2 × ED50 . |
|---|---|---|---|---|---|
| RPMI8226 | 3.31 ± 1.69 | 2.01 ± 0.67 | 2.30 ± 0.55 | 0.70 ± 0.01 | 0.43 ± 0.01 |
| KMS11 | 0.16 ± 0.70 | 0.05 ± 0.01 | 0.06 ± 0.01 | 0.10 ± 0.01 | 0.17 ± 0.03 |
| OPM2 | 0.12 ± 0.01 | 0.20 ± 0.02 | 0.29 ± 0.02 | 0.38 ± 0.04 | 0.30 ± 0.02 |
| Cell line . | Dose 1: ED50/8 . | Dose 2: ED50/4 . | Dose 3: ED50/2 . | Dose 4: ED50 . | Dose 5: 2 × ED50 . |
|---|---|---|---|---|---|
| RPMI8226 | 3.31 ± 1.69 | 2.01 ± 0.67 | 2.30 ± 0.55 | 0.70 ± 0.01 | 0.43 ± 0.01 |
| KMS11 | 0.16 ± 0.70 | 0.05 ± 0.01 | 0.06 ± 0.01 | 0.10 ± 0.01 | 0.17 ± 0.03 |
| OPM2 | 0.12 ± 0.01 | 0.20 ± 0.02 | 0.29 ± 0.02 | 0.38 ± 0.04 | 0.30 ± 0.02 |
CI values for RV and BTZ were generated using Calcusyn software. Synergism was determined per Chou-Talalay method; bold type indicates CI <1, denoting a synergistic response, CI >1 denotes an antagonistic response, and CI = 1 denotes an additive response.